News

Rezo Therapeutics Appoints Derek Hicks as CEO

Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, today announced that Derek Hicks was appointed CEO. With more than 25 years of leadership in the pharmaceutical and biotech sectors, Derek brings a strong track record of...

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the closing of its previously announced business combination with Helix Acquisition Corp. II (formerly Nasdaq: HLXB) (“Helix”), a special...

Tahoe Therapeutics Raises $30M to Build World’s Largest Dataset for Training AI Models of Human Cell

Tahoe Therapeutics today announced $30 million in new funding to build the definitive foundational dataset for training Virtual Cell Models. With this, the team will generate one billion single-cell datapoints, mapping one million drug-patient interactions, a scale previously impossible. The...

Do These Two Cancer Drugs Have What It Takes to Beat Alzheimer’s?

Scientists at UC San Francisco and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that occur in the brain during Alzheimer’s, potentially slowing or even reversing its symptoms. More

Dr. Nicole Jiam, Director of the UCSF Otolaryngology Innovation Center, receives a $1.25M National Science Foundation SBIR Phase II award.

UCSF Innovation Ventures congratulates Dr. Nicole Jiam, Director of the UCSF Otolaryngology Innovation Center, and the Co-Founder/CEO of IIAM Health, a healthtech venture, on receiving a $1.25M National Science Foundation SBIR Phase II award. Together with Dr. David Conrad, Dr. Jiam received...

Welcome Michael Nall as CEO and Board Director of Exai Bio

We’re excited to welcome Michael Nall as CEO and Board Director of Exai Bio. Mike brings decades of diagnostics and commercial expertise that will be instrumental as we scale our RNA- and AI-based liquid biopsy platform and early detection efforts.

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Sana Biotechnology, a company focused on changing the possible for patients through engineered cells, today announced six-month follow-up results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune (HIP...

Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today published a new peer-reviewed study in Neuron, a Cell Press journal, titled “Human stem cell-derived GABAergic interneuron development reveals early...

Biotia Partners with Leading Korean Pharmaceutical Company to Advance Infectious Disease Diagnostics in Remote Regions -- Including in Space

Biotia, a biotechnology company pioneering the development of novel infectious disease diagnostics, today announced its selection as an awardee in the Humans in Space (HIS) Challenge, a global innovation program led by South Korea–based Boryung Corporation.

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Aclarion, a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the first patient enrollment in the CLARITY (C hronic L ow b A ck pain R andomized I ...